1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
2. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-428.
3. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood. 2003;102:4527-4534.
4. Faderl S, Gandhi V, O'Brien S, et al. Clofarabine is active in myelodysplastic syndrome (MDS) [abstract]. Blood. 2006;108. Abstract 2660.
5. Aguayo A. The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr Hematol Rep. 2004;3:184-191.